Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
Status:
Active, not recruiting
Trial end date:
2025-02-20
Target enrollment:
Participant gender:
Summary
The main purpose of the study was to investigate whether nilotinib treatment can be safely
suspended with no recurrence of CML in selected patients who responded optimally on this
treatment